Spero Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Hi, good day. My name is Louise Chen. I'm the large cap pharma, biopharma, and biotech analyst here at Cantor. I would like to introduce you today Sath Shukla, the President and CEO of Spero Therapeutics.
Sath, maybe to start, you could give us your company vision, what Spero is focused on, and how do you think about the company over the next three to five years.
Okay. Thanks for having me, Louise. The company was founded roughly 10 years ago to then combat the growing threat of antibiotic resistance. Over the past few years, particularly with our acquisition of an asset in NTM, the company now sees itself as a leader in rare and infectious diseases.
We have multiple late-stage assets that we hope will provide differentiated therapies in areas of high unmet patient need and strong economic prospects. That's been the mandate for the company over the past several years. And over the next three to five years, it's continuing execution in
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
